Descriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related problems associated with semaglutide across international reporting systems.
Key findingDescriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related pr
What the researchers found
Descriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related problems associated with semaglutide across international reporting systems.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Six GLP-1 drugs analyzed: exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from the WHO VigiAccess database.
How the study worked
In publication.
Who was studied
Global pharmacovigilance reports for six GLP-1 drugs from the WHO VigiAccess database
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.
Current drug safety
Citation
Amirthalingam, Palanisamy. (2025). A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.. Current drug safety. https://doi.org/10.2174/0115748863367086250420011411